Skip to Main Content
Diseases of the Kidney & Urinary Tract, Phase II-III

Treating Kidney Disease in Patients with APOL1

What is the purpose of this trial?

If you are 18-65 years old, diagnosed with kidney disease, and not diabetic, you may be eligible for a clinical trial that is testing an investigational medication to treat APOL1-Mediated Kidney Disease (AMKD). AMKD is caused by genetic variations, which occur commonly in people with African ancestry, and can increase your risk of reaching end-stage kidney disease. Interested participants will receive investigational genetic testing to see if they carry the disease-causing APOL1 genes. Qualified participants will be compensated for study-related time and reimbursement for travel.

  • Trial with
    Vertex Pharmaceuticals, Inc.
  • Ages
    18 years - 60 years
  • Gender

Contact Information

For more information about this study, including how to volunteer, contact Lawrence Ullman Jr.

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact, or call 877.978.8343 for more information.

  • Last Updated
  • Study HIC